408 related articles for article (PubMed ID: 24983709)
1. Cluster analysis and characterization of response to mepolizumab. A step closer to personalized medicine for patients with severe asthma.
Ortega H; Li H; Suruki R; Albers F; Gordon D; Yancey S
Ann Am Thorac Soc; 2014 Sep; 11(7):1011-7. PubMed ID: 24983709
[TBL] [Abstract][Full Text] [Related]
2. Severe eosinophilic asthma treated with mepolizumab stratified by baseline eosinophil thresholds: a secondary analysis of the DREAM and MENSA studies.
Ortega HG; Yancey SW; Mayer B; Gunsoy NB; Keene ON; Bleecker ER; Brightling CE; Pavord ID
Lancet Respir Med; 2016 Jul; 4(7):549-556. PubMed ID: 27177493
[TBL] [Abstract][Full Text] [Related]
3. Weight-adjusted Intravenous Reslizumab in Severe Asthma with Inadequate Response to Fixed-Dose Subcutaneous Mepolizumab.
Mukherjee M; Aleman Paramo F; Kjarsgaard M; Salter B; Nair G; LaVigne N; Radford K; Sehmi R; Nair P
Am J Respir Crit Care Med; 2018 Jan; 197(1):38-46. PubMed ID: 28915080
[TBL] [Abstract][Full Text] [Related]
4. Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial.
Pavord ID; Korn S; Howarth P; Bleecker ER; Buhl R; Keene ON; Ortega H; Chanez P
Lancet; 2012 Aug; 380(9842):651-9. PubMed ID: 22901886
[TBL] [Abstract][Full Text] [Related]
5. Blood eosinophil count is a useful biomarker to identify patients with severe eosinophilic asthma.
Katz LE; Gleich GJ; Hartley BF; Yancey SW; Ortega HG
Ann Am Thorac Soc; 2014 May; 11(4):531-6. PubMed ID: 24606022
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of mepolizumab in Japanese patients with severe eosinophilic asthma.
Shimoda T; Odajima H; Okamasa A; Kawase M; Komatsubara M; Mayer B; Yancey S; Ortega H
Allergol Int; 2017 Jul; 66(3):445-451. PubMed ID: 28110896
[TBL] [Abstract][Full Text] [Related]
7. Eosinophil's role remains uncertain as anti-interleukin-5 only partially depletes numbers in asthmatic airway.
Flood-Page PT; Menzies-Gow AN; Kay AB; Robinson DS
Am J Respir Crit Care Med; 2003 Jan; 167(2):199-204. PubMed ID: 12406833
[TBL] [Abstract][Full Text] [Related]
8. Mepolizumab improves clinical outcomes in patients with severe asthma and comorbid conditions.
Gibson PG; Prazma CM; Chupp GL; Bradford ES; Forshag M; Mallett SA; Yancey SW; Smith SG; Bel EH
Respir Res; 2021 Jun; 22(1):171. PubMed ID: 34098955
[TBL] [Abstract][Full Text] [Related]
9. A study to evaluate safety and efficacy of mepolizumab in patients with moderate persistent asthma.
Flood-Page P; Swenson C; Faiferman I; Matthews J; Williams M; Brannick L; Robinson D; Wenzel S; Busse W; Hansel TT; Barnes NC;
Am J Respir Crit Care Med; 2007 Dec; 176(11):1062-71. PubMed ID: 17872493
[TBL] [Abstract][Full Text] [Related]
10. Baseline blood eosinophil count as a predictor of treatment response to the licensed dose of mepolizumab in severe eosinophilic asthma.
Albers FC; Licskai C; Chanez P; Bratton DJ; Bradford ES; Yancey SW; Kwon N; Quirce S
Respir Med; 2019 Nov; 159():105806. PubMed ID: 31751853
[TBL] [Abstract][Full Text] [Related]
11. Economic analysis of the phase III MENSA study evaluating mepolizumab for severe asthma with eosinophilic phenotype.
Basu A; Dalal A; Canonica GW; Forshag M; Yancey SW; Nagar S; Bell CF
Expert Rev Pharmacoecon Outcomes Res; 2017 Apr; 17(2):121-131. PubMed ID: 28277854
[TBL] [Abstract][Full Text] [Related]
12. Mepolizumab for prednisone-dependent asthma with sputum eosinophilia.
Nair P; Pizzichini MM; Kjarsgaard M; Inman MD; Efthimiadis A; Pizzichini E; Hargreave FE; O'Byrne PM
N Engl J Med; 2009 Mar; 360(10):985-93. PubMed ID: 19264687
[TBL] [Abstract][Full Text] [Related]
13. Mepolizumab for Eosinophilic Chronic Obstructive Pulmonary Disease.
Pavord ID; Chanez P; Criner GJ; Kerstjens HAM; Korn S; Lugogo N; Martinot JB; Sagara H; Albers FC; Bradford ES; Harris SS; Mayer B; Rubin DB; Yancey SW; Sciurba FC
N Engl J Med; 2017 Oct; 377(17):1613-1629. PubMed ID: 28893134
[TBL] [Abstract][Full Text] [Related]
14. Mepolizumab reduces exacerbations in patients with severe eosinophilic asthma, irrespective of body weight/body mass index: meta-analysis of MENSA and MUSCA.
Albers FC; Papi A; Taillé C; Bratton DJ; Bradford ES; Yancey SW; Kwon N
Respir Res; 2019 Jul; 20(1):169. PubMed ID: 31362741
[TBL] [Abstract][Full Text] [Related]
15. Impact of baseline clinical asthma characteristics on the response to mepolizumab: a post hoc meta-analysis of two Phase III trials.
Lemiere C; Taillé C; Lee JK; Smith SG; Mallett S; Albers FC; Bradford ES; Yancey SW; Liu MC
Respir Res; 2021 Jun; 22(1):184. PubMed ID: 34158028
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of Potential Continuation Rules for Mepolizumab Treatment of Severe Eosinophilic Asthma.
Gunsoy NB; Cockle SM; Yancey SW; Keene ON; Bradford ES; Albers FC; Pavord ID
J Allergy Clin Immunol Pract; 2018; 6(3):874-882.e4. PubMed ID: 29258789
[TBL] [Abstract][Full Text] [Related]
17. Assessing the value of mepolizumab for severe eosinophilic asthma: a cost-effectiveness analysis.
Whittington MD; McQueen RB; Ollendorf DA; Tice JA; Chapman RH; Pearson SD; Campbell JD
Ann Allergy Asthma Immunol; 2017 Feb; 118(2):220-225. PubMed ID: 27923549
[TBL] [Abstract][Full Text] [Related]
18. Rapid and Consistent Improvements in Morning PEF in Patients with Severe Eosinophilic Asthma Treated with Mepolizumab.
Ortega H; Menzies-Gow A; Llanos JP; Forshag M; Albers F; Gunsoy N; Bradford ES; Yancey SW; Kraft M
Adv Ther; 2018 Jul; 35(7):1059-1068. PubMed ID: 29949045
[TBL] [Abstract][Full Text] [Related]
19. Long-term Efficacy and Safety of Mepolizumab in Patients With Severe Eosinophilic Asthma: A Multi-center, Open-label, Phase IIIb Study.
Lugogo N; Domingo C; Chanez P; Leigh R; Gilson MJ; Price RG; Yancey SW; Ortega HG
Clin Ther; 2016 Sep; 38(9):2058-2070.e1. PubMed ID: 27553751
[TBL] [Abstract][Full Text] [Related]
20. Characterization of asthma exacerbations in primary care using cluster analysis.
Ortega H; Miller DP; Li H
J Asthma; 2012 Mar; 49(2):158-69. PubMed ID: 22300042
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]